Table 1

Structures of carbohydrate determinants used in this study

The disialyl Lewisa and disialyl Lewisc determinants were shown previously to be preferentially expressed on nonmalignant epithelial cells of digestive organs, whereas (mono-) sialyl Lewisa determinant was known to be expressed predominantly on cancer cells, suggesting that a decrease in 2 → 6 sialylation on malignant transformation is involved in the abnormal accumulation of sialyl Lewisa in cancer tissues (13 14 15) . “R” stands for “→ 3Galβ1 → 4Glaβ1 → ceramide” in the synthetic determinants used in the enzyme-linked immunosorbent assays in experiments described in Fig. 4 <$REFLINK> .

DeterminantStructureSpecific antibody
Disialyl Lewisa (2 → 3, 2 → 6 disialyl Lewisa)NeuAcα2NeuAcα2FH7
36
Galβ1→3GlcNAcβ1→R
4
Fucα1
Sialyl Lewisa (2 → 3 sialyl Lewisa, monosialyl Lewisa)NeuAcα2
N19-9
3
Galβ1→3GlcNAcβ1→R
4
Fucα1
Disialyl Lewisc (2 → 3, 2 → 6 disialyl Lewisc)NeuAcα2NeuAcα2FH9
36
Galβ1→3GlcNAcβ1→R